Abbonarsi

Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood - 05/03/23

Doi : 10.1016/j.jbspin.2022.105501 
Alice Combier a, Camelia Frantz a, Julien Wipff a, Romain Bazeli b, Muriel Elhai a, Antoine Feydy b, Pierre Quartier c, Gertrude Touanga Ngoti a, Marion Thomas a, Chantal Deslandre a, Jérôme Avouac a, Yannick Allanore a,
a Rheumatology Dpt, Cochin hospital, Paris Cité University, Paris, France 
b Radiology B, Cochin hospital, Paris Cité University, Paris, France 
c RAISE Reference Centre for Rare Diseases, Paediatric immunology-haematology and rheumatology unit, Necker-Enfants Malades hospital, Assistance Publique-Hôpitaux de Paris, Paris, France 

Corresponding author at: AP–HP, Department of Rheumatology, Paris Descartes University Cochin Hospital, 27, rue du Faubourg Saint-Jacques, Paris 75014, France.AP–HP, Department of Rheumatology, Paris Descartes University Cochin Hospital27, rue du Faubourg Saint-JacquesParis75014France

Highlights

Polyarticular juvenile arthritis (pJIA) is responsable of structural damage.
RF and ACPA are important biomarkers to predict structural damage in pJIA, their respective performance in adult pJIA is unknown.
ACPA could bring an additional value to RF for pJIA patients regarding structural damage.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Objectives

Polyarticular juvenile idiopathic arthritis (pJIA) is a subset of juvenile idiopathic arthritis (JIA), divided into two subtypes according to the presence of rheumatoid factor: pJIA without rheumatoid factor (pJIA RF-) and pJIA with positive rheumatoid factor (pJIA RF+), this latter is characterised with more structural damage. Anti-citrullinated peptide antibodies (ACPA) are often associated with RF. The respective performance of ACPA versus RF in structural outcome in pJIA, and in particular in adulthood pJIA remains unknown. Therefore, the aim of this study was to determine whether ACPA could be of value to assess structural damage in pJIA persisting in adulthood.

Methods

Patients with pJIA and available data for ACPA, RF and X-ray were included retrospectively. Structural damage was assessed by two independent blinded investigators using Sharp Van Der Heijde scores.

Results

56 pJIA adult patients were included: 62% (35/56) had pJIA RF+ and 38% (21/56) pJIA RF-. ACPA positivity in pJIA was significantly associated with presence of RF (96% vs 26%, P<0.001). RF positivity was significantly associated with higher Sharp van Der Heijde erosion and total scores (respectively P<0.01 and P<0.05). There were higher Sharp Van Der Heijde erosion, joint space narrowing and total scores in the pJIA ACPA+ subgroup than in the pJIA ACPA- subgroup, although there was no statistical significance. However, when adjusted on disease duration, pJIA ACPA+ patients had significantly higher erosion and total scores than pJIA ACPA- patients (P<0.05), and pJIA ACPA+ patients required more bDMARDs than pJIA ACPA- patients (P<0.05). Moreover, pJIA patients with high Sharp van Der Heijde joint space narrowing and total scores had significantly higher ACPA levels (P<0.01). A correlation was identified between ACPA levels and Sharp van Der Heijde total score (r=0.54, P<0.05). In the pJIA RF+ subgroup the presence of ACPA was associated with additional structural damage compared to no ACPA: sharp Van Der Heijde erosion, joint space narrowing and total scores were higher in the pJIA RF+ ACPA+ subgroup than in the pJIA RF+ ACPA- subgroup although these results did not reach significance.

Conclusion

Our results suggest that pJIA RF+ ACPA+ adult patients may have a more severe articular phenotype than pJIA RF+ ACPA- patients. ACPA could bring an additional value to RF for pJIA patients regarding structural damage. Altogether our results show that RF and ACPA are associated with structural damage measured by Sharp Van Der Heijde score in pJIA persisting in adulthood.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Polyarticular juvenile idiopathic arthritis, Anti-citrullinated peptide antibodies, Rheumatoid factor, Risk stratification, Structural damage, SHARP Van Der Heijde Score

Abbreviations : pJIA, pJUA RF+, pJIA RF-


Mappa


© 2022  Société française de rhumatologie. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 90 - N° 2

Articolo 105501- marzo 2023 Ritorno al numero
Articolo precedente Articolo precedente
  • Post-traumatic stress disorder prior to diagnosis is as rare in spondyloarthritis as in non-inflammatory rheumatic conditions and rheumatoid arthritis
  • Angelique Fan, Baptiste Glace, Bruno Pereira, Sandrine Malochet-Guinamand, Marion Couderc, Sylvain Mathieu, Anne Tournadre, Martin Soubrier, Jean-Jacques Dubost
| Articolo seguente Articolo seguente
  • Intravenous anakinra to curb cytokine storm in adult-onset Still's disease and in macrophage activation syndrome: A case series
  • Sara Bindoli, Paola Galozzi, Andrea Doria, Paolo Sfriso

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.